First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors - Concepedia

Concepedia

Publication | Closed Access

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

539

Citations

17

References

2011

Year

Timothy A. Yap, Yan Li, Amita Patnaik, Ivy Fearen, David Olmos, Kyriakos P. Papadopoulos, Richard D. Baird, Liliana Delgado, Adekemi Taylor, Lisa Lupinacci,

Journal of Clinical Oncology

Abstract

MK-2206 was well tolerated, with evidence of AKT signaling blockade. Rational combination trials are ongoing to maximize clinical benefit with this therapeutic strategy.

References

	Year	Citations

Page 1